Stock Price
28.09
Daily Change
4.77%
Yearly
-28.62%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AcelRx Pharmaceuticals 0.61 0.05 8.71% -57.66%
Alimera Sciences 4.98 0.30 6.41% 14.75%
Alexion Pharmaceuticals 182.50 0 0% 70.54%
Arena Pharmaceuticals 52.66 2.59 5.17% -23.98%
BioMarin Pharmaceutical 86.12 1.88 2.23% 9.30%
Cytokinetics 37.47 1.31 3.62% 124.91%
DBV Technologies 2.88 0.07 2.49% -0.69%
Dynavax Technologies 14.45 1.06 7.92% 196.11%
Flexion Therapeutics 9.12 -0.02 -0.22% -17.76%
Gilead Sciences 69.65 0.15 0.22% 13.86%
Heron Therapeutics 9.02 0.06 0.67% -51.00%
Insmed 28.09 1.28 4.77% -28.62%
Mirati Therapeutics 137.50 5.49 4.16% -42.76%
Novartis 80.76 0.23 0.29% -11.46%
Iveric bio Inc. 14.47 0.64 4.63% 108.80%
Ultragenyx Pharmaceutical 84.44 5.55 7.04% -38.67%
Regeneron Pharmaceuticals 635.09 10.09 1.61% 27.75%
Seattle Genetics 146.44 0.43 0.29% -20.61%
Sarepta Therapeutics 85.33 3.63 4.44% -45.58%
Vertex Pharmaceuticals 205.22 0.16 0.08% -10.71%

Indexes Price Day Year
NASDAQ 15687 461.76 3.03% 24.67%
US2000 2254 50.31 2.28% 17.52%

Insmed
Insmed Incorporated is a global biopharmaceutical company. The Company's product, ARIKAYCE (amikacin liposome inhalation suspension) is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders.